A drug developed at MSKCC and Columbia University has won approval from the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma.
MSKCC is now poised to take greater advantage of a new era in cancer research and education with the opening of a state-of-the-art research center, the establishment of a new graduate school, and the founding of a novel research program in human oncology.
MSKCC is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig. Each of the six US centers will receive $20 million cash this year.
Harry Smith, anchor of CBS's The Early Show, was the keynote speaker for MSKCC's celebration of National Survivorship Day. Hundreds of patients and their families listened as he gave his perspective on the role of families and caregivers in the lives of people who have been diagnosed with cancer.
A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to build on its strong scientific and clinical programs with the goal of translating revolutionary advances made in understanding how cancer works at the cellular level into equally dramatic progress in controlling it.
The Starr Foundation announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions -- including MSKCC -- in the fight against cancer.
Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.
MSKCC researchers report that flavopiridol -- a natural product-based compound being investigated as a cancer drug -- represents a possible new treatment for gastrointestinal stromal tumor (GIST), the most common sarcoma of the gastrointestinal tract.
Almost three-fourths of pediatric cancer survivors will have a chronic health problem within 30 years after the cancer diagnosis, according to investigators from MSKCC, St. Jude Children's Research Hospital, and other institutions.
A multi-institutional study led by MSKCC pediatric endocrinologist Charles A. Sklar has identified the incidence of and risk factors for early menopause in childhood cancer survivors.
MSKCC researchers have demonstrated in mice that red blood cell precursors derived from bone marrow stem cells could be engineered to produce a secreted protein at therapeutic levels over a prolonged period.
A resident of Roosevelt Island, NY, Jaqueline Barnes, RN, has been recognized for outstanding patient care with a New York Times Job Market "Tribute to Nurses" award. Out of 500 nominees, Barnes is one of four nurses to receive the award - and the only honoree from the Northeast region.
James A. Fagin has been appointed a Member of MSKCC, Chief of the Endocrinology Service in the Department of Medicine, and a member of the Human Oncology and Pathogenesis Program.
Hepatobiliary surgeon Ronald P. DeMatteo has been named Vice Chair of the Department of Surgery at MSKCC and Head of the department's new Division of General Surgical Oncology.
News@MSKCC provides journalists with news and information from Memorial Sloan-Kettering Cancer Center and is released six times a year.
For more information about these and other potential story ideas, contact Memorial Sloan-Kettering's Department of Public Affairs at: 212-639-3573 or at mediastaff@mskcc.org
